scholarly journals Is High-Dose Chemotherapy After Primary Chemotherapy a Therapeutic Option for Patients With Primary Mediastinal Nonseminomatous Germ Cell Tumor?

2006 ◽  
Vol 12 (10) ◽  
pp. 1085-1091 ◽  
Author(s):  
Giuseppe Luigi Banna ◽  
Ugo De Giorgi ◽  
Benvenuto Ferrari ◽  
Luca Castagna ◽  
Marco Alloisio ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Therapeutic Option ◽  
High Dose Chemotherapy ◽  
Cell Tumor ◽  
Primary Chemotherapy ◽  
High Dose ◽  
Nonseminomatous Germ Cell Tumor

scholarly journals Induction chemotherapy, surgical resection, and high-dose chemotherapy for mediastinal nonseminomatous germ-cell tumor

2005 ◽  
Vol 130 (4) ◽  
pp. 1205-1206 ◽  
Author(s):  
Hiroshi Date ◽  
Kiura Katsuyuki ◽  
Hiroshi Ueoka ◽  
Masahiro Tabata ◽  
Katsuyuki Hotta ◽  
...  
Keyword(s):  
Germ Cell ◽  
Surgical Resection ◽  
Induction Chemotherapy ◽  
Germ Cell Tumor ◽  
High Dose Chemotherapy ◽  
Cell Tumor ◽  
High Dose ◽  
Nonseminomatous Germ Cell Tumor

scholarly journals Salvage Resection of Mediastinal Nonseminomatous Germ Cell Tumor in a Patient with Extrathoracic Involvement upon Progression following High-Dose Chemotherapy

2021 ◽  
pp. 1254-1260
Author(s):  
Jia-Ling Chou ◽  
David Tse
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
High Dose Chemotherapy ◽  
Cell Tumor ◽  
High Dose ◽  
First Line ◽  
Term Survival ◽  
Nonseminomatous Germ Cell Tumor ◽  
Mediastinal Disease

Primary mediastinal nonseminomatous germ cell tumor with extrathoracic metastases is associated with a very high mortality rate, and there is no consensus regarding optimal upfront therapy. Once patients fail the first-line treatment, salvage therapy often fails to effectively control the disease. Resection of the residual mediastinal mass does not appear to achieve long-term control in those who have extrathoracic metastases following conventional first-line systemic therapy. We report a case where a young man presented with symptomatic brain metastases as well as extensive visceral involvement of the liver, small intestine, and lungs. He was successfully managed with multimodality treatment including high-dose chemotherapy with hematopoietic stem cell support following standard first-line chemotherapy, resection of mediastinal disease, lung metastasectomy, and stereotactic brain radiation. He has achieved long-term survival.

Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features

2011 ◽  
Vol 29 (3) ◽  
pp. 284-290 ◽  
Author(s):  
Ugo De Giorgi ◽  
Giovanni Rosti ◽  
Roberto Salvioni ◽  
Giorgio Papiani ◽  
Michela Ballardini ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
High Dose Chemotherapy ◽  
Cell Tumor ◽  
High Dose ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Prognostic Features

Control of relapsed germ cell tumor and SLE nephritis by high-dose chemotherapy and autologous hematopoietic cell transplantation

2013 ◽  
Vol 9 (9) ◽  
pp. 1401-1406 ◽  
Author(s):  
Christos Kosmas ◽  
Theodora Papachrysanthou ◽  
Theodoros Daladimos ◽  
Aggelos Athanasopoulos ◽  
Nicolas Tsavaris ◽  
...  
Keyword(s):  
Germ Cell ◽  
Cell Transplantation ◽  
Germ Cell Tumor ◽  
Hematopoietic Cell Transplantation ◽  
High Dose Chemotherapy ◽  
Cell Tumor ◽  
Hematopoietic Cell ◽  
High Dose ◽  
Autologous Hematopoietic Cell Transplantation

Clinical Impact of Germ Cell Tumor Cells in Apheresis Products of Patients Receiving High-Dose Chemotherapy

2001 ◽  
Vol 19 (12) ◽  
pp. 3029-3036 ◽  
Author(s):  
C. Bokemeyer ◽  
A. J.M. Gillis ◽  
K. Pompe ◽  
F. Mayer ◽  
B. Metzner ◽  
...  
Keyword(s):  
Germ Cell ◽  
Tumor Cells ◽  
Germ Cell Tumor ◽  
Peripheral Blood ◽  
High Dose Chemotherapy ◽  
Cell Tumor ◽  
High Dose ◽  
Placental Alkaline Phosphatase ◽  
Rt Pcr ◽  
Β Hcg

PURPOSE: High-dose chemotherapy (HD-Ctx) followed by autologous peripheral-blood stem-cell (PBSC) transplantation is currently investigated in patients with poor prognosis or relapsed metastatic germ cell tumor (GCTs). This study analyzed the presence and the clinical importance of contaminating tumor cells in PBSC preparations used to support HD-Ctx in GCT patients. PATIENTS AND METHODS: Seven targets for reverse transcription polymerase chain reaction (RT-PCR)-based detection of GCT cells were able to detect seminomatous and different histologic variants of nonseminomatous tumor cells. PBSC preparations from 57 patients were investigated for the presence of contaminating tumor cells using this set of targets, including beta human chorionic gonadotropin (β-hCG), fibronectin (EDB variant), epidermal growth factor receptor (EGFR), CD44 (v8 to 10 variant), germ cell and placental alkaline phosphatase (AP), human endogenous retrovirus type K (ENV and GAG), and XIST. Samples of PBSC preparations from four healthy donors for allogenic transplantations as well as blood specimens from 10 healthy volunteers served as negative controls. RESULTS: Fifty patients (43 first-line and seven second-line Ctx) were assessable. Combining all RT-PCR results, 29 PBSC preparations (58%) were positive for tumor-specific amplification products (HERV-K 0, fibronectin 4, XIST 14, β-hCG 19, AP 19, CD44 24, EGFR 26). Ten (35%) of 29 patients who underwent transplantation with positive PBSC preparations and seven (33%) of 21 patients with negative PBSC preparations have suffered relapse or progression (not significant [ns]). With a median follow-up of 22 months (2 to 66) post–HD-Ctx projected 3-year survival rates are 68% (RT-PCR+) and 58% (RT-PCR−) (ns). None of the 10 control peripheral-blood samples showed positivity for any of the targets studied. CONCLUSION: GCT cells can be detected in more than 50% of PBSC preparations using a RT-PCR approach with multiple targets. Despite the presence of tumor cells, retransplantation of the PBSC products did not effect long-term outcome. Factors such as responsiveness to chemotherapy and tumor mass seem to overcome the importance of potentially re-infused tumor cells.

Sign in / Sign up

Export Citation Format

Share Document